Tarsus Pharmaceuticals, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Tarsus reported Q2 2026 XDEMVY net product sales of $173.9M (up 69% YoY from $102.7M in Q2 2025) and raised full-year 2026 guidance to $685–705M. The company announced a pending acquisition of Alkeus Pharmaceuticals to add ALK-001, a Phase 3 oral therapy for Stargardt disease (36,000+ U.S. patients). Tarsus priced a $125M private placement financing to fund the acquisition. Cash position: $449.7M as of June 30, 2026. Net loss narrowed to $18.6M (Q2 2026) vs. $20.3M (Q2 2025).
Why this rating
Strong core-product growth (69% YoY) narrows losses and funds pipeline expansion. Alkeus acquisition adds late-stage retina asset; ~7% of market cap in financing is material but manageable. Meaningful but not transformational for $1.7B company.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.